pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Neupro
drug
save

rotigotine ER

Marketedupdated 5mo ago
by UCB SA
Approved
community read0 votes

indications

investigational
Parkinson's Disease

all catalysts(0)

nothing on the calendar yet

Trials studying rotigotine ER

  • phase1Bioequivalence and Adhesion of a Rotigotine Patch in Healthy Subjectscompletedn=35
  • N/AAdhesion and Safety of Rotigexole Compared to Neupro®not yet recruitingn=40
  • phase4Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Diseaseterminatedn=1
  • phase2Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Diseasecompletedn=38
  • phase3A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrometerminatedn=10
  • phase3A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Causeterminatedn=23

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 1, 2027
332 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (24)

  • Mar 1, 2032formulationUS 9925150
  • Mar 1, 2032formulationUS 9925150
  • Mar 1, 2032formulationUS 9925150
  • Mar 1, 2032formulationUS 9925150
  • Mar 1, 2032formulationUS 9925150
  • Mar 1, 2032formulationUS 9925150
  • Dec 22, 2030formulationUS 101305894.2y
  • Dec 22, 2030formulationUS 101305894.2y
  • Dec 22, 2030formulationUS 101305894.2y
  • Dec 22, 2030formulationUS 101305894.2y
  • Dec 22, 2030formulationUS 101305894.2y
  • Dec 22, 2030formulationUS 101305894.2y
  • Dec 22, 2030formulationUS 103501744.2y
  • Dec 22, 2030formulationUS 103501744.2y
  • Dec 22, 2030formulationUS 103501744.2y
  • Dec 22, 2030formulationUS 103501744.2y
  • Dec 22, 2030formulationUS 103501744.2y
  • Dec 22, 2030formulationUS 103501744.2y
  • Sep 1, 2027formulationUS 8246979332d
  • Sep 1, 2027formulationUS 8246979332d
  • Sep 1, 2027formulationUS 8246979332d
  • Sep 1, 2027formulationUS 8246979332d
  • Sep 1, 2027formulationUS 8246979332d
  • Sep 1, 2027formulationUS 8246979332d

News(0)

no news has mentioned this drug yet

brand
Neupro
generic
rotigotine
indication
Parkinson's Disease
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?